Methods and materials are disclosed for testing biomarkers in a subject suffering from inflammatory bowel disease (IBD) are described herein. Such detection can be useful for diagnosing and treating ulcerative colitis (UC) and Crohn's disease (CD), two forms of IBD that are otherwise difficult to distinguish. The method includes measuring the level of one or more of several biomarkers, including HD5 or MMP-7, which are expressed differentially in patents with UC and CD. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.

The present disclosure relates generally to biomarkers of fibrosis. More particularly, the present disclosure relates to salivary biomarkers and their use in methods, apparatuses, compositions and kits for determining an indicator that is useful for assessing a likelihood of a presence, absence or degree of liver fibrosis in a human subject. In particular embodiments, the disclosed methods, apparatuses, compositions and kits are used to determine an indicator for assessing a likelihood of a presence, absence or development of liver cirrhosis in a subject.

This invention related to a method for diagnosing a skin displaying signs of aging, based on measuring the level of expression of the gene encoding the IDE. The present invention also relates to a method for the cosmetic treatment of skin. This invention also relates to a method for identifying a compound for reducing the signs of the aging of the skin as well as a kit.

Embodiments of the present disclosure relates to ivaltinostat combination therapy for treating pancreatic cancer in subjects having low levels of serological protein biomarkers with negative correlation to progression-free survival (PFS).

A biosensor for detecting a biomarker in a bodily fluid, secretion or exudation is described that includes a first electrode, a second electrode, an electrode coating and a mechanical electrode stabilizer. The biomarker is an enzyme catalyzing a chemical reaction in which a singularity or plurality of constituents of the electrode coating are chemically altered by the breaking of covalent chemical bonds when being in contact with the same. The electrode coating can be a natural or synthetic substrate of the biomarker. The first electrode and the second electrode are electrically conductive and are kept in a substantially constant and uniform distance from each other by means of the mechanical electrode stabilizer. The exposed electrically conductive surface of at least one of the first electrode and the second electrode are substantially fully covered by the electrode coating.

The present invention relates to a method for selecting highly potent stem cells for the treatment of neurological disease using TIMP-1, MCP-1, GRO, and IL-6, and a pharmaceutical composition for the prevention or treatment of neurological disease. According to the present invention, a specific combination of markers including TIMP-1, MCP-1, GRO, and IL-6 can be used as a biomarker for selecting stem cells with superior therapeutic (ameliorating) potential in the treatment of neurological disease. Moreover, the application of stem cells exhibiting increased expression or activity of TIMP-1, MCP-1, GRO, and IL-6 factors or the use of substances that regulate (particularly upregulate) these factors in stem cells has a remarkable therapeutic effect on neurological disease due to having high efficacy (potency) and efficiency. Furthermore, the present invention presents the higher therapeutic potential of allogeneic stem cell transplantation.